RxDoctor Payments Data

Diana Doan-Nguyen

Family · Costa Mesa, CANPI 1225792369

Payments from drug & device makers

$1,281in general payments, 2019–2025

Across 54 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$182
  • Ardelyx, Inc.$143
  • Novo Nordisk$124
  • Gilead$122
  • Bayer$121
  • Takeda Pharmaceuticals U.S.A., Inc.$115
  • plus $475 from 11 others

What the payments were for

  • Food & beverage$1,25498%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,281 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$22,541
Medicare patients
169
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide40$26,766
Mesalamine20$3,166
Dexlansoprazole DrDexlansoprazole12$2,903
Sucralfate21$2,701
Famotidine133$1,922
Pantoprazole Sodium199$1,885
Omeprazole86$819
Levothyroxine Sodium52$621
Atorvastatin Calcium52$554
Hydrocortisone27$455
Rosuvastatin Calcium29$382
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl30$378
Albuterol Sulfate HfaAlbuterol Sulfate19$333
Tenofovir Disoproxil Fumarate13$281
Gabapentin12$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$66$26,76640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Costa Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →